Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin Trial in Prader-Willi Syndrome
NCT02013258Phase 1Completed
- Sponsor
- University of Florida
- Start
- Mar 2015
- Primary completion
- Aug 2015
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in Prader-Willi syndrome (PWS) (2 arms), sponsored by University of Florida. Primary endpoint: Safety of intranasal oxytocin at 3 months. Started Mar 2015; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT02013258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013258.